Gene therapy for sickle cell disease durability

Chattip Prueksapraopong, Donald B. Kohn · 2026

Read Gene therapy for sickle cell disease durability by Chattip Prueksapraopong, Donald B. Kohn (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13523825.txt.

Description

This 2026 letter by Prueksapraopong and Kohn replies to a comment on their article about lentiviral gene therapy for sickle cell disease. The exchange concerns what durability should mean for a one time genetic treatment. The authors agree that two measures differ: gene marking, the share of blood cells carrying the inserted gene, and protein expression, whether the gene still works.

In their study only one patient kept both marking and expression long term. One kept marking but lost expression, and two lost both over time. The authors contrast earlier trials in immune diseases where dozens of patients kept both. They suggest chronic marrow inflammation in sickle cell disease may shorten the survival of corrected stem cells. Prueksapraopong argues durability should mean lasting clinical benefit backed by both measures.

Catalog record

CREATORChattip Prueksapraopong, Donald B. Kohn
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13523825

Browse the full library · About the Tower of Babel